Physician
All Children's Pediatric Clinic P.A.
All Children's Pediatric Clinic P.A. was paid $16.01M by Medicaid between Jan 2018 and Dec 2024, across 91 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoALL CHILDREN'S PEDIATRIC CLINIC P.A.
MCALLEN, TX 78504
MCALLEN, TX 78504
33aNPI1730257106assigned 12/01/2006
33bProvider typePediatrics Physician
28Total paid$16.01M
24GClaims771,922
24DCodes billed91
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#14 of 1,136
Median peer was paid$329K
This provider vs. median49×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,177 | $137K | |
| 2019 | 3,834 | $96K | |
| 2020 | 26,071 | $622K | |
| 2021 | 197,762 | $3.64M | |
| 2022 | 259,291 | $5.31M | |
| 2023 | 166,688 | $3.66M | |
| 2024incomplete | 113,099 | $2.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 153,997 | 125,339 | $5.21M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 13% | 48,824 | 42,551 | $2.07M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5.4% | 65,096 | 59,731 | $870K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.2% | 11,760 | 11,570 | $830K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.2% | 11,350 | 11,098 | $827K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.8% | 57,107 | 26,710 | $765K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.6% | 10,766 | 10,523 | $739K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.6% | 15,187 | 13,298 | $729K |
| S8301 | Infection control supplies, not otherwise specified | 3.5% | 81,611 | 63,488 | $560K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.1% | 7,137 | 6,815 | $491K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.8% | 44,460 | 20,645 | $442K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 56,802 | 48,801 | $357K |
79 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 24,628 | $303K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 10,471 | $227K |
| 99000 | <1% | 15,826 | $157K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,736 | $148K |
| 99429 | <1% | 4,139 | $125K | |
| 99381 | <1% | 1,650 | $123K | |
| 87807 | <1% | 9,028 | $96K | |
| 99050 | <1% | 5,955 | $84K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,126 | $77K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,593 | $76K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,592 | $75K |
| 86328 | <1% | 845 | $74K | |
| 90461 | <1% | 13,864 | $65K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 7,227 | $52K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,771 | $52K |
| 0071A | <1% | 1,100 | $42K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,061 | $39K |
| 0072A | <1% | 808 | $32K | |
| 0001A | <1% | 905 | $27K | |
| 0002A | <1% | 738 | $25K | |
| 94010 | <1% | 782 | $18K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 239 | $18K |
| 99383 | <1% | 223 | $18K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13,907 | $17K |
| CP002 | <1% | 1,706 | $16K | |
| 81002 | <1% | 5,813 | $16K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 372 | $15K |
| 99382 | <1% | 177 | $14K | |
| 94016 | <1% | 780 | $14K | |
| 96160 | <1% | 5,870 | $9K | |
| 0003A | <1% | 236 | $9K | |
| 87428 | <1% | 241 | $9K | |
| 92567 | <1% | 720 | $9K | |
| 99384 | <1% | 53 | $5K | |
| 0011A | <1% | 210 | $4K | |
| 99051 | <1% | 336 | $3K | |
| 0012A | <1% | 139 | $3K | |
| 84030 | <1% | 717 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,912 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 760 | $2K |
| 0073A | <1% | 40 | $2K | |
| 86580 | <1% | 230 | $1K | |
| 0081A | <1% | 35 | $1K | |
| 81025 | <1% | 166 | $1K | |
| 69210 | <1% | 41 | $1K | |
| 97802 | <1% | 2,132 | $1K | |
| 97169 | <1% | 58 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | $965.64 |
| 97170 | <1% | 38 | $900.00 | |
| 90651 | <1% | 2,303 | $518.64 | |
| 96380 | <1% | 13 | $212.25 | |
| 90670 | <1% | 4,893 | $203.15 | |
| 90620 | <1% | 1,241 | $193.49 | |
| 90680 | <1% | 3,859 | $181.90 | |
| 90619 | <1% | 1,214 | $170.11 | |
| 92587 | <1% | 17 | $119.84 | |
| 90686 | <1% | 4,982 | $116.50 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 103 | $5.28 |
| 90671 | <1% | 1,463 | $1.52 | |
| 90744 | <1% | 1,131 | $0.48 | |
| 90734 | <1% | 1,689 | $0.31 | |
| 90633 | <1% | 3,479 | $0.30 | |
| 90710 | <1% | 2,935 | $0.19 | |
| 90715 | <1% | 1,790 | $0.17 | |
| 90648 | <1% | 435 | $0.12 | |
| 90696 | <1% | 1,374 | $0.08 | |
| 90716 | <1% | 221 | $0.03 | |
| 90707 | <1% | 190 | $0.03 | |
| 91307 | 0% | 1,994 | $0.00 | |
| 90698 | 0% | 2,927 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 33 | $0.00 |
| 90697 | 0% | 2,485 | $0.00 | |
| 90381 | 0% | 12 | $0.00 | |
| 91301 | 0% | 374 | $0.00 | |
| 91300 | 0% | 2,014 | $0.00 | |
| 91308 | 0% | 28 | $0.00 | |
| 90700 | 0% | 594 | $0.00 | |
| 90713 | 0% | 12 | $0.00 | |
| 90658 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTORRES, FADI (MEDICAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| All Children's Pediatric Clinic P.A. | Edinburg, TX | $26K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.